Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 1,341 - 1,360 results of 21,342 for search '(( significance ((greater decrease) OR (we decrease)) ) OR ( significant decrease decrease ))', query time: 0.43s Refine Results
  1. 1341
    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups.

    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups. by David Vagni (8060432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1342
    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort.

    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1343
    S1 Raw data -

    S1 Raw data - by Dominic Michael Rasp (19959412)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 1344
    S2 Raw data -

    S2 Raw data - by Dominic Michael Rasp (19959412)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 1345
    Summary of HSS and LSI during the LIST.

    Summary of HSS and LSI during the LIST. by Dominic Michael Rasp (19959412)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 1346
    EF-24 induces significant transcriptional changes in K-562 cells.

    EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1347
    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period.

    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1348
    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods.

    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1349
    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya.

    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1350
    Uganda: enrolment, time to IVA, mortality, admissions and readmissions.

    Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1351
    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods.

    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1352
    Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site.

    Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1353
    Lymphocyte proliferation assay following combination therapy with NDV.

    Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:
  14. 1354
    Tumor volume measurements.

    Tumor volume measurements. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:
  15. 1355
    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold change (2<sup>-ΔΔCt</sup>). miRNAs with a fold change greater than 1.3 in the vehicle group and at the 0.75–1.3 range (orange striped area) in the Bz and Bz + PTX therapy groups were considered to have a restored expression. They were selected for further analysis on IPA software. (A) The expression of miRNAs was altered in the infected group and an expression was restored after Bz therapy. (B) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (C) Diseases and disorders pathway analysis. (D) The expression of miRNAs was altered in the infected group and restored upon Bz + PTX therapy. (E) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (F) Diseases and disorders pathway analysis. Significant intervals

    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold chang... by Glaucia Vilar-Pereira (686134)

    Published 2025
    Save to List
    Saved in:
  16. 1356
    IL-10 levels in tumor lysates post-treatment.

    IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:
  17. 1357
    Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10<sup>7</sup> CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated withA. TYL (3 times, q7D), B. LMC (3 times, q7D), C. sham (3 times, q7D), D. OTC (3 times, q4D), E. OTC (1 time) and F. sham (3 times, q4D. Red-dotted line represents calculated inoculation dose (CFU/bee) administered on day 1. *, represents significant differences from D3 bacterial load, with P < 0.05.

    Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10<sup>7</sup> CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

    Published 2025
    Save to List
    Saved in:
  18. 1358
    CTL response following combination therapy with NDV.

    CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:
  19. 1359
    Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx

    Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

    Published 2025
    “…</p>Objective<p>This study aims to elucidate the clinical implications of concurrent AICDA and IKBKB homozygous variants in a pediatric patient diagnosed with hyper-IgM syndrome.</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”
    Save to List
    Saved in:
  20. 1360
    Sequence of <i>DpAP2</i> promoter.

    Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: